Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pelacarsen (TQJ230) plus inclisiran background therapy in ASCVD with elevated LDL-C and Lp(a)
CTR20252131Phase 3Active
- Sponsor
- Novartis
- Start
- Oct 2025
- Modality
- Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Modified DNA Oligonucleotides → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of pelacarsen in atherosclerotic disease, coronary arteriosclerosis, cerebrovascular disease, arteriosclerosis obliterans, lipoprotein(a) hyperlipoproteinemia (Lp(a)), sponsored by Novartis. Started Oct 2025; status: active.
02
Drugs
pelacarsen
03
Conditions
atherosclerotic diseasecoronary arteriosclerosiscerebrovascular diseasearteriosclerosis obliteranslipoprotein(a) hyperlipoproteinemia (Lp(a))
Beyond the preview
Go deeper on CTR20252131.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20252131.